Could OM Pharma’s Broncho-Vaxom study change how clinicians assess recurrent RTI prevention?
Find out how OM Pharma’s Broncho-Vaxom data could reshape RTI prevention, real-world evidence and non-antibiotic care strategies.
Why Intellia’s lonvo-z Phase 3 data could raise expectations for one-time HAE treatment
Find out how Intellia’s lonvo-z Phase 3 data could change expectations for one-time hereditary angioedema treatment.